Key facts
- This page summarizes Arun Kumar Pillai's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Feb 2022, 16:09.
Arun Kumar Pillai - 01 Feb 2022 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- OTLK
- Reported as of
- 01 Feb 2022
- Net transaction value
- -$3,125,000
- Reporting owner signature
- /s/ Arun Pillai Kumar, By: Lawrence Kenyon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Arun Kumar Pillai filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 01 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$3,125,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OTLK
transaction
Common Stock
Other
- Transaction value
- $3,125,000
- Shares
- -2,500,000
- Change %
- -9.8%
- Price
- $1.25
- Shares after
- 22,982,529
- Date
- 01 Feb 2022
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These securities are held of record by BioLexis Pte Ltd. ("BioLexis") and represent the number securities in which Arun Kumar Pillai ("Kumar"), a natural person, may be deemed to have an indirect pecuniary interest in by virtue of the relationships described herein. Tenshi Life Sciences Private Limited and Tenshi Life Sciences Pte. Limited (collectively, "Tenshi"), both private investment vehicles controlled by Kumar, are beneficial owners of BioLexis and Kumar is the holder of a controlling interest in Tenshi. Kumar disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.
Footnote F2
On January 31, 2022, GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, entered into a securities purchase agreement with each Tenshi entity, pursuant to which GMS Pharma purchased from Tenshi approximately 4.9% of the outstanding shares of BioLexis (the "Share Sale"), which corresponds to 2,500,000 shares of the Issuer held by BioLexis. The Share Sale closed on February 1, 2022.
Footnote F3
BioLexis has designated one representative to serve on the Issuer's board of directors. This report shall not be deemed an admission that Kumar is the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.